(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/057158 A1

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2010/055745

(22) International Filing Date:
5 November 2010 (05.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/280,567 5 November 2009 (05.11.2009) US

(71) Applicant *(for all designated States except US)*: **TALIGEN THERAPEUTICS, INC.** [US/US]; 245 First Street, Suite 1100, Cambrige, MA 02142 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **HOLERS, V., Michael** [US/US]; 242 S. Hudson Street, Denver, CO 80246 (US). **RISITANO, Antonio, M.** [IT/IT]; Via Pansini 5, I-80131 Naples (IT).

(74) Agents: **XIAO, Jian** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/057158 A1

(54) **Title**: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, HEMOLYTIC ANEMIAS AND DISEASE STATES INVOLVING INTRAVASCULAR AND EXTRAVASCULAR HEMOLYSIS

(57) **Abstract**: Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.